Comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea, and anorexia: a single-blind, randomized, crossover study

Feng, Feng Yi; Zhang, Pin; He, Yi; Li, Yu Hong; Zhou, Mei Zhen; Cheng, Gang; Yamamoto, Masakazu

doi:10.1016/s0011-393x(00)90017-1

Cited by 27 publications

(20 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical studies showed that the pharmacological action of ramosetron was long lasting [11][12][13] . Moreover, in clinical studies, ramosetron showed longer-term effects than granisetron and tropisetron [14][15][16][17][18] . In the present study, we investigated the difference in efficacy between ramosetron and ondansetron.…”

Section: Discussionmentioning

confidence: 99%

Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study

Shi

Yang

et al. 2007

Chemotherapy

View full text Add to dashboard Cite

Background: This study observed and compared the preventive effects of ramosetron and ondansetron on gastrointestinal side effects caused by cisplatin-containing chemotherapy. Methods: Fifty patients with malignant tumors undergoing their first chemotherapy were randomly divided into two groups, and each group received 0.3 mg of ramosetron and 16 mg of ondansetron in a prospective crossover comparison study. Results: Data were collected for analysis of the therapeutic effect in 47 cases and for adverse events in 50 cases. Both drugs showed similar results in regard to chemotherapy-induced gastrointestinal side effects, emesis and appetite loss on day 1, but by day 5, ramosetron was significantly better than ondansetron in terms of controlling appetite loss. From days 3–5, ramosetron tended to be more effective than ondansetron in its antiemetic action. The incidence of headache, fatigue and constipation was the same for both drugs. Conclusions: Ramosetron is a long-lasting and safe antiemetic agent.

show abstract

Section: Discussionmentioning

confidence: 99%

Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study

Shi

Yang

et al. 2007

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…Ramosetron and granisetron were more effective in suppressing the emetic effects of ACNU than cisplatin, as 70% of patients receiving ramosetron and 73.7% of patients receiving granisetron were able to eat normally at 24 hours after ACNU administration compared to 48% and 33.7%, respectively, of patients after cisplatin administration. 3) The effect of i.v. ramosetron was longer than that of i.v.…”

Section: Discussionmentioning

confidence: 99%

Comparative Clinical Study of the Anti-Emetic Effects of Oral Ramosetron and Injected Granisetron in Patients With Malignant Glioma Undergoing ACNU Chemotherapy

Yano

Makino

Nakamura

et al. 2005

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

The effectiveness of ramosetron tablets and granisetron injection was compared for reducing the frequency of nausea, vomiting, and anorexia in patients with malignant glioma undergoing ACNU chemotherapy. Patients with malignant glioma to be treated with ACNU chemotherapy were randomly assigned to receive oral ramosetron (20 patients) or intravenous granisetron (19 patients) prior to ACNU injection. Gastrointestinal toxicity within 48 hours of ACNU injection was compared to that in patients who had received ACNU chemotherapy with dopamine D2 receptor-blocker as a historical control group. Within 24 hours of the administration of ACNU, 15 of the 20 patients treated with ramosetron and 16 of the 19 treated with granisetron were nausea-free, and 14 of the former and 14 of the latter regained their normal appetite. There was no significant difference in the anti-emetic effects. Ten of the 17 controls experienced no vomiting within 6 hours of the injection of ACNU, five were nausea-free within 24 hours, and two retained their normal appetite within 24 hours. Oral ramosetron has the same anti-anorectic and anti-emetic effects as intravenous granisetron. Ramosetron tablets are less expensive and are easy to take, so should be on the list of first-choice anti-emetic drugs for patients treated with ACNU chemotherapy.

show abstract

“…Both of the study drugs were administered immediately before cisplatin treatment and 6, 24 and 48 h after treatment. Each dose of antiemetic agent used in this study (granisetron, 3 mg, and ramosetron, 0.3 mg) are levels that have been shown to be effective in Japanese and Chinese patients [10,23]. Both groups also received methylprednisolone sodium, 250 mg, immediately before and 6 h after cisplatin treatment.…”

Section: Discussionmentioning

confidence: 99%

A Double-Blind, Crossover, Randomized Comparison of Granisetron and Ramosetron for the Prevention of Acute and Delayed Cisplatin-Induced Emesis in Patients with Gastrointestinal Cancer: Is Patient Preference a Better Primary Endpoint?

Koizumi¹,

Tanabe²,

Nagaba³

et al. 2003

Chemotherapy

View full text Add to dashboard Cite

Background: Serotonin receptor antagonists are recommended by the American Society of Clinical Oncology for the prevention of acute and delayed chemotherapy-induced emesis. However, the most effective agent in this class of antiemetic drugs for preventing emesis has not been clearly defined. We therefore performed a double-blind, crossover, randomized, controlled trial comparing the efficacy of granisetron and ramosetron, using patient preference as the primary endpoint. Methods: Thirty patients receiving two courses of combined chemotherapy (including ≧60 mg/m² cisplatin) for gastric or esophageal cancer were randomly assigned to the granisetron-ramosetron group (treatment phase 1: granisetron, 3 mg; treatment phase 2: ramosetron, 0.3 mg) or the ramosetron-granisetron group (treatment phase 1: ramosetron, 0.3 mg; treatment phase 2: granisetron, 3 mg). All patients received methylprednisolone sodium, 250 mg i.v., during each treatment phase. Results: The efficacy of granisetron and ramosetron was similar in terms of the suppression of emesis and appetite status. However, the majority of patients (19/30, 63.3%) expressed a preference for granisetron, as compared with 9 patients (30.0%) who preferred ramosetron; 2 patients (6.7%) had no preference (χ² test: p = 0.008; Fisher’s exact test: p = 0.015). Conclusions: (1) A significant proportion of patients prefer granisetron over ramosetron for the prevention of chemotherapy-induced emesis. (2) Granisetron and ramosetron possess similar effectiveness for the suppression of emesis. (3) The variable of ‘patient preference’ should be accepted as a primary endpoint of antiemetic drug efficacy.

show abstract

Comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea, and anorexia: a single-blind, randomized, crossover study

Cited by 27 publications

References 4 publications

Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study

Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study

Comparative Clinical Study of the Anti-Emetic Effects of Oral Ramosetron and Injected Granisetron in Patients With Malignant Glioma Undergoing ACNU Chemotherapy

A Double-Blind, Crossover, Randomized Comparison of Granisetron and Ramosetron for the Prevention of Acute and Delayed Cisplatin-Induced Emesis in Patients with Gastrointestinal Cancer: Is Patient Preference a Better Primary Endpoint?

Contact Info

Product

Resources

About